Illumina’s Genetic Testing Business is Booming

 Illumina’s Genetic Testing Business is Booming

Sales at the leader in gene sequencing systems, Illumina, keep exceeding its expectations. The company has raised its growth guidance three times this year, forecasting last week that 2021 year sales will now rise 36%.

The company reported that sales in the September quarter rose 40% from the year-earlier period to $1.1 billion. Earnings rose nearly 50% to $221 million, or $1.45 a share, including about 25 cents worth of costs and share dilution from Illumina’s acquisition of the cancer blood-screening firm Grail.

Friday,…

Related post